A retrospective, observational, multicenter cohort study of natalizumab extended interval dosing efficacy on MRI activity compared with the standard interval dosing in Italy
Latest Information Update: 02 Jun 2021
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Therapeutic Use
- 02 Jun 2021 New trial record
- 15 May 2021 Results published in the Journal of the Neurological Sciences